Antibody Drug Conjugate Market Analysis

Global Antibody Drug Conjugate Market Overview

The antibody drug conjugate market size was valued at USD 9.56 billion in 2023 and is projected to grow from USD 10.97 Billion in 2023 to USD 33.57 billion by 2032, exhibiting a compound annual growth rate (CAGR) of 15.01% during the forecast period (2024 - 2032). Growing Research and Development Activities for the Development of Novel Therapeutics and rising Incidence of Cancer are the key market drivers enhancing the market growth.

Ambrx Biopharma, Inc., or Ambrx, is a clinical-stage biopharmaceutical company with a proprietary synthetic biology technology platform to design and develop next-generation antibody drug conjugates (ADCs). Johnson & Johnson announced that it has entered into a definitive agreement to acquire Ambrx Biopharma, Inc. in 2024. This will be an all-cash merger transaction, with a total equity value of approximately $2.0 billion, or $1.9 billion net of estimated cash acquired. With the goal of maximizing the effectiveness and safety of its candidate therapeutics in a variety of cancer indications, Ambrx is advancing a focused portfolio of clinical and preclinical programs. These programs include ARX517, a proprietary ADC that targets PSMA for metastatic castration-resistant prostate cancer (mCRPC); ARX788, a proprietary ADC that targets human epidermal growth factor receptor 2 (HER2) for metastatic HER2+ breast cancer; and ARX305.

By 2024, Japan's Daiichi Sankyo is intensifying its efforts to take the lead in the rapidly expanding antibody-drug conjugate (ADC) market, following the announcement in October of plans to acquire two production subsidiaries. Daiichi is investing about 1 billion euros ($1.08 billion) to expand its production and development site at Pfaffenhofen a der Ilm, which is located just north of the company's European headquarters in Munich, with the goal of creating a "international innovation center."

A relationship with a significant biopharmaceutical partner for the commercial-scale filling of ADCs was extended, according to an announcement made in 2023 by Lonza, a global manufacturing partner to the pharmaceutical, biotech, and nutraceutical markets. At its Stein (CH) facility, Lonza is required by the agreement to build a specialized aseptic cGMP filling line on a commercial scale.

Antibody Drug Conjugate Market Trends

• Growing Research and Development Activities to boost market growth

The rising incidence of cancer, the growing elderly population, and the rising R&D activities for the discovery of novel treatments are also significant drivers of the market expansion for antibody drug conjugate. The ability to use the precision of monoclonal antibodies toward specific antigens for the delivery of potential cytotoxic medicines, with increased activity and less toxicity as compared to chemotherapies, makes ADCs one of the fastest-growing treatments for cancer patients. In order to deliver highly potential cytotoxic drug molecules to the precise tumor-related antigens for cancer treatment, ADCs use antibodies as a carrier. The approval of 10 ADCs, include Adcetris and Kadcyla that target the Cd30 and HER2 antigen sites, respectively, is evidence of recent developments in ADC technology.

The market CAGR for antibody drug conjugate is anticipated to experience profitable expansion as research and development activities increase. For instance, at the 62nd annual meeting of the American Society of Hematology 2020 on December 7, 2020, ADC Therapeutics SA, a late-stage biotechnology company with an oncology focus, introduced the most recent clinical data of its two major initiatives, Loncastuximab-Tesirine (Lonca) and Camidanlumab-Tesirine (Cami). An antibody-drug conjugate (ADC) called loncastuximab tesirine is made up of a human monoclonal antibody that targets the human Cluster of Differentiation (CD)19 and is linked to a pyrrolobenzodiazepine (PBD) dimeric cytotoxin. The pyrrolobenzodiazepine (PBD) dimer payload tesirin is conjugated to a monoclonal antibody that binds to CD25 to create the antibody drug conjugate (ADC) known as camidanlumab Tesirin.

The Antibody Drug Conjugate market's growing investments are anticipated to strengthen the pipeline for antibody drug conjugate and expand its applications, both of which will contribute to the market's expansion. For instance, in 2022, Spirea Limited obtained GBP 2.4 million in fundraising with contributions from famous British and American investors. With these funding, the company will start developing its pipeline of better and distinctive ADCs for the treatment of solid tumors. Additionally, Mersana Therapeutics, Inc. and Janssen Biotech, Inc., one of the Pharmaceutical Companies of Johnson & Johnson, entered into a research cooperation and license agreement in February 2022 to find novel ADCs for three targets. Mersana will use its expertise, as well as its exclusive Dolasynthen platform, to identify fresh ADC product candidates. The studied market is therefore anticipated to increase significantly throughout the study period as a result of the factors mentioned. But during the course of the projected year, it's anticipated that the market growth would be restrained by strict governmental regulations, costly procedures, and a shortage of funds.

Antibody Drug Conjugate Market Segment Insights

Antibody Drug Conjugate Type Insights

The market segments of antibody drug conjugate, based on type, includes Monoclonal Antibodies, and Linker. The Monoclonal Antibodies segment held the majority share in 2021 contribution to around ~60-65% in respect to the antibody drug conjugate market revenue. This is primarily owing to the rising prevalence of various type cancer and growing demand of cost-efficient biosimilar monoclonal antibodies.

Figure 2: Antibody Drug Conjugate Market, by Type, 2021 & 2030 (USD Billion)

Source: Secondary Research, Primary Research, MRFR Database and Analyst Review

Antibody Drug Conjugate Applications Insights

The antibody drug conjugate market segmentation, based on applications, includes Leukemia, and Lymphoma. The Leukemia segment dominated the market in 2021. The rising incidence of leukaemia worldwide, which is anticipated to increase demand for treatments for the disease. ly, almost all forms of leukaemia, including ALL and CML, are becoming more common. For instance, the Leukemia & Lymphoma Society (LLS) released estimates estimating that in the US, leukaemia will be diagnosed in 60,530 million persons by the year 2020. Similar to this, the International Agency for Research on Cancer predicted that in 2020 there will be approximately 474,519 new cases of leukaemia worldwide. It is anticipated that a rise in patient populations ly will accelerate market growth.

Antibody Drug Conjugate Regional Insights

By Region, the study provides the market insights into North America, Europe, Asia-Pacific and Rest of the World. North America is predicted to hold dominant position in the worldwide market of antibody drug conjugate during the forecast period, due mainly to the launch of new products or approvals. For instance, on April 23, 2021, the next-generation oncology-focused biotechnology company ADC Therapeutics SA announced that ZYNLONTA (Loncastuximab Tesirinelpyl) has received FDA approval for the therapy of refractory or relapsed large B-cell lymphoma. Based on its overall response rate, the U.S. FDA granted fast approval to ZYNLONTA, an antibody-drug combination that target CD19.

Further, the major countries studied in the market report are: The U.S, Canada, Germany, France, UK, Italy, Spain, China, Japan, India, Australia, South Korea, and Brazil.

Figure 3:  ANTIBODY DRUG CONJUGATE MARKET SHARE BY REGION 2021 (%)

Source: Secondary Research, Primary Research, MRFR Database and Analyst Review

Europe antibody drug conjugate market accounts for the second-largest market share due to the advancement in the medical technology, obese population and rising ageing population in the region is anticipated to support the market’s growth during the forecast period. Further, the Germany market of antibody drug conjugate held the largest market share, and the UK market of antibody drug conjugate was the fastest growing market in the European region

The Asia-Pacific market of Antibody Drug Conjugate projected to grow at a CAGR of 18.7% during the forecast period. The approval of new antibody-drug conjugates in the area is responsible for the region's expansion. For instance, Japan's MHLW gave Astellas' enfortumab vedotin for therapy of metastatic or locally advanced urothelial cancer priority review in May 2021. Moreover, China market of antibody drug conjugate held the largest market share, and the India market of antibody drug conjugate was the fastest growing market in the Asia-Pacific region

Antibody Drug Conjugate Key Market Players & Competitive Insights

Major market players are spending a lot of money on R&D to increase their product lines, which will help the market grow of antibody drug conjugate even more. Market participants are also taking a range of strategic initiatives to grow their worldwide footprint, with key market developments such as new research and development, contractual agreements, mergers and acquisitions, increased investments, and collaboration with other organizations. Competitors in the antibody drug conjugate industry must offer cost-effective treatment and therapy to expand and survive in an increasingly competitive and rising market environment.

One of the primary business strategies adopted by manufacturers in the antibody drug conjugate industry to benefit clients and expand the market sector is to manufacture locally to reduce operating costs. In recent years, antibody drug conjugate industry has provided therapy with some of the most significant benefits. The antibody drug conjugate market major player such as ADC Therapeutics, Takeda Pharmaceutical Company Ltd., GlaxoSmithKline Plc, Hoffmann-La Roche Ltd., and others are working to expand the market demand by investing in research and development activities.

The aseptic filling of highly potent ADCs and containment lyophilization will be made possible by the new dedicated filling line. The extra filling capabilities bolster Lonza's ability and adaptability to support the commercial and clinical supply of bioconjugates even more.

The acquisition, which was announced on Monday, would bring together Pfizer's strength and scale with Seagen's technology in 2023, according to a statement from Pfizer CEO Albert Bourla. Pfizer's oncology business, which already offers Ibrance, a therapy for breast cancer, and therapies for prostate cancer, generated $12 billion in sales last year. Seagen, which changed its name from Seattle Genetics in 2020, saw total revenue climb by 25% last year to about $2 billion. The business reduced its loss to $610 million in the previous year.

ADC Therapeutics a biotechnology company was established in 2011 and its headquarters is in Switzerland. ADC Therapeutics is a leader in the field of antibody-drug conjugates (ADCs). Its fully integrated value chain includes research, translational and biochemistry, manufacturing, and controls, all of which are specialised capabilities specific to the lifecycle of ADCs. Our extensive pipeline includes ADCs that are in clinical trials for cancers of the hematologic and solid human cancers. The company has a strong, tested technology foundation in highly effective PBD-based ADCs, and we are growing our reach to build assets of the next generation. In Nov. 2022, IGM Biosciences, Inc., a clinical-stage biotechnology company specialising in the development of IgM antibodies, and ADC Therapeutics SA recently announced that they have collaborated on a clinical trial and entered into a supply agreement to test the efficacy of imvotamab, a novel IgM CD20 x CD3 T cell engaging bispecific antibody from IGM, and ZYNLONTA® (loncastuximab tesirine-lpyl) (NHL).

Also, Seagen Inc. is an American biopharmaceutical company that focuses on creating and commercializing innovative, enabling monoclonal antibody-based treatments for treatment of cancer. The company was established in 1997 and its headquarters is in Bothell, Washington, United States. In March 2022, an exclusive collaboration agreement was signed by Sanofi and Seagen Inc. to create, develop, and market antibody-drug conjugates (ADCs) targeting up to three different cancer targets. The collaboration will make use of the exclusive monoclonal antibody (mAb) technology from Sanofi and the exclusive ADC technology from Seagen.

Key Companies in the antibody drug conjugate market includes

• ADC Therapeutics


• Takeda Pharmaceutical Company Ltd.


• GlaxoSmithKline Plc


• Hoffmann-La Roche Ltd.


• Daiichi Sankyo Company Ltd.


• Pfizer Inc.


• Seagen Inc.


• Gilead Sciences Inc.


• Astellas Pharma, among others

Antibody Drug Conjugate Industry Developments

February 2022:Eli Lilly and Company received exclusive rights from ImmunoGen Inc. to research, develop, and market antibody-drug conjugates (ADCs) that are directed at targets chosen by Lilly relying on ImmunoGen's novel camptothecin technology. This exclusive right was granted as part of a , multi-year definitive licence agreement.

September 2021:The FDA of the United States Administration granted STRO-002 to Sutro Biopharma, Inc. the Fast Track designation. It is an antibody-drug conjugate (ADC) that targets the folate receptor alpha (FolR) and is used to treat people with platinum-resistant epithelial ovarian, primary peritoneal cancer whom has received one to three lines of systemic therapy in the previous.

Antibody Drug Conjugate Market Segmentation:

Antibody Drug Conjugate Type Outlook

• Monoclonal Antibodies


• Linker

Antibody Drug Conjugate Product Outlook

• Adcertis


• Kadcyla

Antibody Drug Conjugate Technology Outlook

• Immunogen Technology


• Immunomedics Technology

Antibody Drug Conjugate Application Outlook

• Leukemia


• Lymphoma

Antibody Drug Conjugate End-User Outlook

• Biotechnology Companies

Antibody Drug Conjugate Regional Outlook

• North America
  
  
  
  • US
  
  
  • Canada
  
  
  
  


• Europe
  
  
  
  • Germany
  
  
  • France
  
  
  • UK
  
  
  • Italy
  
  
  • Spain
  
  
  • Rest of Europe
  
  
  
  


• Asia-Pacific
  
  
  
  • China
  
  
  • Japan
  
  
  • India
  
  
  • Australia
  
  
  • South Korea
  
  
  • Australia
  
  
  • Rest of Asia-Pacific
  
  
  
  


• Rest of the World
  
  
  
  • Middle East
  
  
  • Africa
  
  
  • Latin America